Analyst firms · Wedbush · GOSS
Wedbush GOSS price target and rating history
Gossamer Bio Inc. (GOSS) · Health Care
Wedbush rates Gossamer Bio Inc. (GOSS) Neutral with a $1 price target, as of its latest action on Feb 24, 2026. It has published 3 rating actions on GOSS since September 2022, including 0 upgrades and 1 downgrade. Across 4 firms with a GOSS price target in the last 12 months, the median target is $1. Wedbush's target matches it.
- Current rating
- Neutral
- Price target
- $1
- Median target, all firms
- $1
- Actions on GOSS
- 3
Wedbush price target on GOSS
Every Wedbush rating on GOSS
- Feb 24, 2026
- Apr 5, 2024
- Sep 19, 2022
How other firms rate GOSS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Chardan Capital Markets | Buy | $160 | Oct 13, 2026 |
| Leerink Partners | Outperform | $1 | Jul 28, 2026 |
| Cantor Fitzgerald | Neutral | Mar 23, 2026 | |
| Wedbush | Neutral | $1 | Feb 24, 2026 |
| Barclays | Equal Weight | $0.30 | Feb 24, 2026 |
Questions about Wedbush and GOSS
- What is Wedbush's price target for GOSS?
- Wedbush's latest stated price target for Gossamer Bio Inc. (GOSS) is $1, from its action on Feb 24, 2026.
- What is Wedbush's rating on GOSS?
- Wedbush rates GOSS Neutral, a neutral rating, as of Feb 24, 2026.
- When did Wedbush last change its view on GOSS?
- On Feb 24, 2026, Wedbush downgrades to Neutral from Outperform, price target $1.
- How does Wedbush's GOSS target compare with other analysts?
- Across 4 firms with a GOSS price target in the last 12 months, the median target is $1. Wedbush's target matches it.
More GOSS rating histories
All Wedbush ratingsGOSS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.